No Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting Medications
Open Access
- 1 September 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 18 (9) , 2562-2564
Abstract
Tamoxifen reduces recurrence risk among women treated for estrogen receptor–positive breast cancer. Its effectiveness partly depends on metabolic activation via cytochrome P450 2D6 (CYP2D6). Some medications compromise CYP2D6 activity and may lower plasma concentrations of active tamoxifen metabolites. We studied the association between concurrent use of tamoxifen and CYP2D6-inhibiting medications and breast cancer recurrence among Danish women diagnosed with early-stage, estrogen receptor–positive breast cancer. Using the Danish Breast Cancer Cooperative Group Registry, we identified 366 cases with local or distant breast cancer recurrence and 366 matched breast cancer controls. We ascertained concurrent prescription of CYP2D6-inhibiting medications during tamoxifen treatment by linking to the national prescription database covering all Danish pharmacies. We computed the breast cancer recurrence odds ratio (OR) and 95% confidence interval for each medication. The pooled recurrence OR was null (OR, 1.0; 95% confidence interval, 0.8-1.3); recurrence ORs for individual drugs ranged from 0.3 to 3.4. The individual ORs followed the pattern expected under a null-centered Gaussian distribution. Null associations were apparent for all drugs after empirical Bayes adjustment for multiple comparisons. Together, these results provide evidence for a null association between drug-compromised CYP2D6 activity and breast cancer recurrence among tamoxifen-treated women. (Cancer Epidemiol Biomarkers Prev 2009;18(9):2562–4)Keywords
This publication has 21 references indexed in Scilit:
- Genotype-guided tamoxifen therapy: time to pause for reflection?The Lancet Oncology, 2009
- Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopramBritish Journal of Cancer, 2008
- The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promiseActa Oncologica, 2008
- Danish Breast Cancer Cooperative Group – DBCG: History, organization, and status of scientific achievements at 30-year anniversaryActa Oncologica, 2008
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- The validity of self‐reported use of hormone replacement therapy among Danish nursesActa Obstetricia et Gynecologica Scandinavica, 2004
- Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor ParoxetineJNCI: Journal of the National Cancer Institute, 2003
- The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z‐4‐hydroxy‐tamoxifen in human liverBritish Journal of Clinical Pharmacology, 2002
- Empirical-Bayes Adjustments for Multiple Comparisons Are Sometimes UsefulEpidemiology, 1991
- Unbiased plotting positions — A reviewJournal of Hydrology, 1978